A Phase I Clinical Study to Evaluate the Safety, Efficacy, and PK/PD Characteristics of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
This is a Phase I Clinical Study to Evaluate the Safety, Efficacy, and PK/PD Characteristics of HSK47977 Tablets in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma.This study includes a Phase Ia dose-escalation stage and a Phase Ib dose-expansion stage, and it is expected to take approximately 2 years.
• Voluntarily sign the informed consent form.
• Age ≥18 years, with no gender restriction.
• Pathologically confirmed patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL).
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.
• Expected survival \>3 months.
• Presence of measurable lesions.
• Adequate organ function.
• Agreement to undergo pathological tissue biopsy.
• Subjects of childbearing potential must agree to comply with the contraceptive requirements of the study.
⁃ No pregnancy plans from screening until at least 3 months after the last dose of the study drug, and voluntary use of effective contraceptive measures.